Prognostic Systems for Lymphomas

Hematology/Oncology Clinics of North America

Volumn 22, Issue 5, 2008, Pages 839-861

  Johnston, Anna ^a   Salles, Gilles ^b  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

Biomarkers; Lymphoma; Micro arrays; Prognosis

Indexed keywords

ANTHRACYCLINE; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; PREDNISONE; PROTEIN BCL 2; PROTEIN P53; RITUXIMAB; VINCRISTINE;

APOPTOSIS; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CYTOGENETICS; DNA MICROARRAY; DRUG EFFICACY; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR LYMPHOMA; FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INTERNATIONAL PROGNOSTIC INDEX; KAPLAN MEIER METHOD; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MORPHOLOGY; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PARAMETER; PERIPHERAL T CELL LYMPHOMA; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SALVAGE THERAPY; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; SURVIVAL TIME; TISSUE MICROARRAY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 54149104638     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2008.07.012     Document Type: Review

References (101)

1. Pulte D., Gondos A., and Brenner H. Ongoing improvement in outcomes for patients diagnosed as having non-hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med 168 (2008) 469-476
2. Sehn L.H., Donaldson J., Chhanabhai M., et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23 (2005) 5027-5033
3. The international non-hodgkin's lymphoma prognostic factors project. A predictive model for aggressive non-hodgkin's lymphoma. N Engl J Med 329 (1993) 987-994
4. Hermans J., Krol A.D., van Groningen K., et al. International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 86 (1995) 1460-1463
5. Lopez-Guillermo A., Montserrat E., Bosch F., et al. Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 12 (1994) 1343-1348
6. Decaudin D., Lepage E., Brousse N., et al. Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients-a study of the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 17 (1999) 2499-2505
7. Perea G., Altes A., Montoto S., et al. Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. Ann Oncol 16 (2005) 1508-1513
8. Armitage J.O., and Weisenburger D.D. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 16 (1998) 2780-2795
9. Gisselbrecht C., Gaulard P., Lepage E., et al. Prognostic significance of T-cell phenotype in aggressive non-hodgkin's lymphomas. Blood 92 (1998) 76-82
10. Gallamini A., Stelitano C., Calvi R., et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103 (2004) 2474-2479
11. Savage K.J., Chhanabhai M., Gascoyne R.D., et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 15 (2004) 1467-1475
12. Sonnen R., Schmidt W.-P., Muller-Hermelink H.K., et al. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. British Journal of Haematology 129 (2005) 366-372
13. Escalón M., Liu N., Yang Y., et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma. Cancer 103 (2005) 2091-2098
14. Ansell S.M., Habermann T.M., Kurtin P.J., et al. Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol 15 (1997) 2296-2301
15. Mounier N., Spina M., Gabarre J., et al. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood 107 (2006) 3832-3840
16. Micallef I.N.M., Remstein E.D., Ansell S.M., et al. The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphoma. Leukemia and Lymphoma 47 (2006) 1794-1799
17. Blay J.Y., Gomez F., Sebban C., et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA Trial. Blood 92 (1998) 3562-3568
18. Bastion Y., and Coiffier B. Is the International Prognostic Index for aggressive lymphoma patients useful for follicular lymphoma patients?. J Clin Oncol 12 (1994) 1340-1342
19. Velders G.A., Kluin-Nelemans J.C., De Boer C.J., et al. Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol 14 (1996) 1269-1274
20. Samaha H., Dumontet C., Ketterer N., et al. Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 12 (1998) 1281-1287
21. Oinonen R., Franssila K., Teerenhovi L., et al. Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients. European Journal of Cancer 34 (1998) 329-336
22. Tiemann M., Schrader C., Klapper W., et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. British Journal of Haematology 131 (2005) 29-38
23. Hoster E., Dreyling M., Klapper W., et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111 (2008) 558-565
24. Kim T.M., Park Y.H., Lee S.-Y., et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIE extranodal NK/T-cell lymphoma, nasal type. Blood 106 (2005) 3785-3790
25. Solal-Celigny P., Roy P., Colombat P., et al. Follicular Lymphoma International Prognostic Index. Blood 104 (2004) 1258-1265
26. Moller M.B., Pedersen N.T., and Christensen B.E. Mantle cell lymphoma: prognostic capacity of the Follicular Lymphoma International Prognostic Index. British Journal of Haematology 133 (2006) 43-49
27. Lee J., Suh C., Park Y.H., et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 24 (2006) 612-618
28. Sehn L.H. Optimal use of prognostic factors in non-hodgkin lymphoma. Hematology Am Soc Hematol Educ Program (2006) 295-302
29. Buske C., Hoster E., Dreyling M., et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108 (2006) 1504-1508
30. Jaffe E.S., Harris N.L., Stein H., et al. Pathology and genetics of tumours of Haematopoietic and Lymphoid tissues (2001), IARC Press, Lyon
31. Salar A., Fernandez de Sevilla A., Romagosa V., et al. Diffuse large B-cell lymphoma: Is morphologic subdivision useful in clinical management?. Eur J Haematol 60 (1998) 202-208
32. Hans C.P., Weisenburger D.D., Vose J.M., et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 101 (2003) 2363-2367
33. Ganti A.K., Weisenburger D.D., Smith L.M., et al. Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience. Ann Oncol 17 (2006) 920-927
34. Ott G., Katzenberger T., Lohr A., et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood 99 (2002) 3806-3812
35. Savage K.J. Aggressive Peripheral T-Cell Lymphomas (Specified and Unspecified Types). Hematology Am Soc Hematol Educ Program 2005 (2005) 267-277
36. Tilly H., Rossi A., Stamatoullas A., et al. Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood 84 (1994) 1043-1049
37. Hoglund M., Sehn L., Connors J.M., et al. Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. Genes Chromosomes Cancer 39 (2004) 195-204
38. Huang J.Z., Sanger W.G., Greiner T.C., et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 99 (2002) 2285-2290
39. Barrans S.L., Evans P.A.S., O'Connor S.J.M., et al. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin Cancer Res 9 (2003) 2133-2139
40. Hummel M., Bentink S., Berger H., et al. A biologic definition of burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354 (2006) 2419-2430
41. Le Gouill S., Talmant P., Touzeau C., et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica 92 (2007) 1335-1342
42. Kanungo A., Medeiros L.J., Abruzzo L.V., et al. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24//c-MYC translocation generally have a poor prognosis. Mod Pathol 19 (2005) 25-33
43. Gascoyne R.D., Aoun P., Wu D., et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93 (1999) 3913-3921
44. Hockenbery D., Nunez G., Milliman C., et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348 (1990) 334-336
45. Lossos I.S., and Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 24 (2006) 995-1007
46. Hermine O., Haioun C., Lepage E., et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 87 (1996) 265-272
47. Gascoyne R.D., Adomat S.A., Krajewski S., et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-hodgkin's lymphoma. Blood 90 (1997) 244-251
48. Mounier N., Briere J., Gisselbrecht C., et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101 (2003) 4279-4284
49. Sanchez-Beato M., Sanchez-Aguilera A., and Piris M.A. Cell cycle deregulation in B-cell lymphomas. Blood 101 (2003) 1220-1235
50. Pescarmona E., Pignoloni P., Puopolo M., et al. p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome. Journal of Pathology 195 (2001) 361-366
51. Moller M.B., Gerdes A.-M., Skjodt K., et al. Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell Non-hodgkin's lymphoma. Clin Cancer Res 5 (1999) 1085-1091
52. Grogan T.M., Lippman S.M., Spier C.M., et al. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood 71 (1988) 1157-1160
53. Miller T.P., Grogan T.M., Dahlberg S., et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood 83 (1994) 1460-1466
54. Jerkeman M., Anderson H., Dictor M., et al. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma-a Nordic Lymphoma Group study. Annals of Hematology 83 (2004) 414-419
55. Determann O., Hoster E., Ott G., et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 111 (2008) 2385-2387
56. Went P., Agostinelli C., Gallamini A., et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic Score. J Clin Oncol 24 (2006) 2472-2479
57. Cuadros M., Dave S.S., Jaffe E.S., et al. Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. J Clin Oncol 25 (2007) 3321-3329
58. Pfreundschuh M., Trümper L., Österborg A., et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. The Lancet Oncology 7 (2006) 379-391
59. Quackenbush J. Microarray analysis and tumor classification. N Engl J Med 354 (2006) 2463-2472
60. Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 (2000) 503-511
61. de Jong D., Rosenwald A., Chhanabhai M., et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications-a study from the lunenburg lymphoma biomarker consortium. J Clin Oncol 25 (2007) 805-812
62. Rosenwald A., Wright G., Chan W.C., et al. The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma. N Engl J Med 346 (2002) 1937-1947
63. Wright G., Tan B., Rosenwald A., et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proceedings of the National Academy of Sciences 100 (2003) 9991-9996
64. Abramson J.S., and Shipp M.A. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 106 (2005) 1164-1174
65. Shipp M.A., Ross K.N., Tamayo P., et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8 (2002) 68-74
66. Savage K.J., Monti S., Kutok J.L., et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102 (2003) 3871-3879
67. Rosenwald A., Wright G., Leroy K., et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to hodgkin lymphoma. J. Exp. Med 198 (2003) 851-862
68. Lossos I.S., Czerwinski D.K., Alizadeh A.A., et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350 (2004) 1828-1837
69. Lossos I.S., Jones C.D., Warnke R., et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 98 (2001) 945-951
70. Winter J.N., Weller E.A., Horning S.J., et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 107 (2006) 4207-4213
71. Bea S., Zettl A., Wright G., et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 106 (2005) 3183-3190
72. Dave S.S., Fu K., Wright G.W., et al. Molecular diagnosis of burkitt's lymphoma. N Engl J Med 354 (2006) 2431-2442
73. Hans C.P., Weisenburger D.D., Greiner T.C., et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103 (2004) 275-282
74. Zinzani P.L., Dirnhofer S., Sabattini E., et al. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. Haematologica 90 (2005) 341-347
75. van Imhoff G.W., Boerma E.-J.G., van der Holt B., et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 24 (2006) 4135-4142
76. Colomo L., Lopez-Guillermo A., Perales M., et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 101 (2003) 78-84
77. Moskowitz C.H., Zelenetz A.D., Kewalramani T., et al. Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. Blood 106 (2005) 3383-3385
78. Nyman H., Adde M., Karjalainen-Lindsberg M.-L., et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 109 (2007) 4930-4935
79. Lenz G., Wright G., Dave S., et al. Gene expression signatures predict overall survial in diffuse large B cell lymphoma treated with rituximab and chop-like chemotherapy. Blood (ASH Annual Meeting Abstracts) 110 (Nov 2007) 348
80. Jais J.-P., Haioun C., Molina T., et al. The expression of 16 genes related to the cell of origine and immune response predicts survival in elderly patients with Diffuse large B-cell lymphoma treated with CHOP and Rituximab. Leukemia (2008 Jul 10) [Epub ahead of print]
81. Glas A.M., Knoops L., Delahaye L., et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 25 (2007) 390-398
82. Dave S.S., Wright G., Tan B., et al. Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells. N Engl J Med 351 (2004) 2159-2169
83. Farinha P., Masoudi H., Skinnider B.F., et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 106 (2005) 2169-2174
84. Canioni D., Salles G., Mounier N., et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 26 (2008) 440-446
85. Alvaro T., Lejeune M., Salvado M.-T., et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 24 (2006) 5350-5357
86. Carreras J., Lopez-Guillermo A., Fox B.C., et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 108 (2006) 2957-2964
87. Lee A.M., Clear A.J., Calaminici M., et al. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 24 (2006) 5052-5059
88. Wahlin B.E., Sander B., Christensson B., et al. CD8+ T-cell content in diagnostic lymph nodes measured by glow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 13 (2007) 388-397
89. Rosenwald A., Wright G., Wiestner A., et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3 (2003) 185-197
90. Martinez-Delgado B., Melendez B., Cuadros M., et al. Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes. Clin Cancer Res 10 (2004) 4971-4982
91. Ballester B., Ramuz O., Gisselbrecht C., et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene 25 (2005) 1560-1570
92. Shin J., Monti S., Aires D.J., et al. Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. Blood 110 (2007) 3015-3027
93. Cerhan J.R., Wang S., Maurer M.J., et al. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood 109 (2007) 5439-5446
94. Haioun C., Itti E., Rahmouni A., et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106 (2005) 1376-1381
95. Spaepen K., Stroobants S., Dupont P., et al. Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 13 (2002) 1356-1363
96. Kostakoglu L., Goldsmith S.J., Leonard J.P., et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 107 (2006) 2678-2687
97. Mikhaeel N.G., Hutchings M., Fields P.A., et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 16 (2005) 1514-1523
98. Rimsza L.M., LeBlanc M.L., Roberts R.A., et al. Major Histocompatibility class II (MHCII) and germinal center associated gene expression correlate with overall survival in ritiximab and CHOP-like treated diffuse large B cell lymphoma (DLBCL) patients using formalin fixed paraffin embedded (FFPE) tissues. Blood (ASH Annual Meeting Abstracts) 110 (Nov 2007) 50
99. Malumbres R., Johnson N.A., Sehn L.H., et al. Paraffin-based 6-gene model predicts outcome of diffuse large B-cell lymphoma patients treated with R-CHOP. Blood (ASH Annual Meeting Abstracts) 110 (Nov 2007) 49
100. Cerhan J.R., Maurer M.J., Hartge P., et al. Polymorphisms in one-carbon metabolism genes and overall survival in diffuse large B-cell lymphoma (DLBCL). ASH Blood (ASH Annual Meeting Abstracts) 110 (Nov 2007) 49
101. Jardin F., Ruminy P., Kerckaert J.-P., et al. Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas. Haematologica 93 (2008) 543-550